JPRN-UMIN000001230
Unknown
未知
Secondary Prevention of Cerebral Infarction Epidemiological Study on Cerebral Microbleeds - SCIENCE Study
SCIENCE Study Protocol Comittee0 sites4,000 target enrollmentJuly 2, 2008
Conditionscerebral infaction
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- cerebral infaction
- Sponsor
- SCIENCE Study Protocol Comittee
- Enrollment
- 4000
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •recurred symptomatic cerebral infarction medicatin of antiplatelet drugs before onset moyamoya disease, AVM, AN, dural AVF previous cerebral contusion previous craniotomy and/or burr hole surgery future surgery and/or intervention for brain and heart previous symptomatic cerebral hemorrhage, other hemorrhagic disease, coagulopathy present malignancy platelet count\<10000/m3 liver dysfunction (AST\>100IU/L, ALT\>100IU/L) renal dysfunction (Cre\>3mg/dl) future moving, diffculties for follow\-up amyloid angiopathy participants in other intervening clinical research
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Prevention of one sort of cerebral vascular stroke (small subcortical strokes) in patients who already suffered one beforeEUCTR2005-003242-34-ESational Institutes of Neurological Disorders: Stroke2,500
Completed
Not Applicable
Primary prevention of cerebrovascular and cardiovascular events with an oral antidiabetic agent in patients with type 2 diabetes at high risk for cerebral infarctioType 2 DiabetesJPRN-UMIN000000846PROFIT-J Study Steering Committee500
Recruiting
Not Applicable
Prevention of secondary stroke by risk factor control and medication adherenceHealth Condition 1: G968- Other specified disorders of central nervous systemCTRI/2021/10/037432Department of Health and Family Welfare
Active, not recruiting
Phase 1
Prevention of Stroke in Survivors of Brain Bleeding with Atrial FibrillatioEUCTR2018-002176-41-ITImperial College of Science, Technology and Medicine654
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000